Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06303284

Post-surgical Outcomes With Anabolic Agent Use in High-risk Ankle Fractures: A Pilot RCT

As the global population ages and the prevalence of poor bone health increases among older patients with ankle fractures, so does the risk of post-surgical complications. Prevention of post-surgical complications is of paramount importance to reducing morbidity, mortality, and healthcare costs.

There is growing evidence to support the use of bone-building medications, such as Teriparatide, in patients who have delayed fracture healing or non-unions; however, these medications have yet to be investigated in elderly patients with ankle fractures at high risk for delayed fracture healing and post-operative complications. This project aims to assess the safety and efficacy of short-term Teriparatide use in improving outcomes in a population most likely to suffer post-operative complications.

The proposed study is a pilot randomized controlled trial (RCT) with patients 60 years or older with an additional risk factor for delayed healing (i.e., osteoporosis, diabetes, vascular disease) who require ankle fracture surgery. Participants will be randomized to receive the study medication (Teriparatide) or placebo for three months. The primary objective of this study is to acquire vital data (i.e., recruitment rates, follow-up rates, adherence to treatment assignment) required to determine the feasibility of a full-scale multi-centre RCT. Additional aims are to evaluate repeat surgery, complications, time-to-union, and 90-day mortality. A complete a socio-economic and feasibility analysis will be completed.

This study will evaluate the novel clinical approach of augmenting surgical fixation with a medication to build bone density and strength, thereby improving bone health, preventing complications, and improving outcomes. This study will also inform planning for a larger clinical trial to reduce the morbidity, mortality, and cost associated with complications in this high-risk population.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

60 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

About this study

Background: Delayed healing, implant failure, loss of reduction, and infection rates are common post-operative complications following ankle fracture fixation among patients aged 60 years or older with compromised soft tissue and/or metabolic challenges. There is growing evidence to support the safety and efficacy of using anabolic agents in achieving osseous union in the setting of delayed fracture healing and nonunion. Teriparatide has been prescribed for the treatment of osteoporosis, with very few serious adverse events reported. Therefore, the goals of the proposed research are to examine the safety and efficacy of Teriparatide use for high-risk acute ankle fractures and to determine the feasibility of a full-scale trial. This new knowledge will inform the implementation of Teriparatide for improved fracture healing.

Specific Aims (SA): The investigators hypothesize that the short-term use of the anabolic agent, Teriparatide, will augment fracture fixation and result in lower complication rates. Our specific aims include: SA1) Evaluate the feasibility of a definitive, full-scale randomized controlled trial comparing Teriparatide with a placebo; SA2) Compare the post-operative complication rate between short-term augmentation with Teriparatide and a placebo; and SA3) Evaluate the safety and efficacy of Teriparatide use.

Methods: This study is a multi-center double-blinded pilot randomized controlled trial (RCT) with patients 60 years or older with an additional risk factor for delayed healing (i.e., osteoporosis, diabetes, vascular disease) who require ankle fracture surgery. Participants will be randomized to receive the study medication (Teriparatide) or placebo for three months. The primary objective of this study is to acquire vital data (i.e., recruitment rates, follow-up rates, adherence to treatment assignment) required to determine the feasibility of a full-scale multi-center RCT. Additional aims are to evaluate repeat surgery, complications, time-to-union, and 90-day mortality. A complete a socio-economic and feasibility analysis will be completed.

Significance: Delayed healing, implant failure, loss of reduction, and infection rates continue to be devastating complications of ankle fracture fixation that profoundly impact patients and their families, surgeons, and the healthcare system. It is imperative that the investigators evaluate innovative strategies for improving outcomes for these high-risk patients. The multi-disciplinary team of investigators has designed this project to generate new knowledge about the safety and efficacy of using Teriparatide in the acute fracture setting in order to reduce complications, morbidity, and mortality in this vulnerable population. By addressing knowledge gaps and promoting evidence-based education and interventions, the project aims to have a sustainable impact on scientific knowledge, clinical practice, and ultimately, the well-being of elderly patients undergoing ankle fracture fixation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Our study will include men and women over 60 years of age presenting to the emergency department with low energy ankle fractures (fall from standing height) requiring surgical treatment and who have one or more of the following risk factors, diabetes, osteoporosis, renal disease, steroid use, smoking history, peripheral neuropathy and/or vascular disease.

Exclusion criteria

  • Individuals will be excluded if they have received previous Teriparatide therapy, or they have hypercalcemia or hyperparathyroidism, as these are precautions to the use of Teriparatide.

Treatment and study plan

subcutaneous Teriparatide injection

Drug

20 µg subcutaneous (SC) Teriparatide injection

Other names: Teriparatide

Placebo

Other

placebo 20 µg subcutaneous saline placebo injection once daily for 3 months in the post-operative ankle fracture population.

Primary outcomes

  1. Participant recruitment rate

    Time frame: 2 years

    Estimate of the mean monthly recruitment rate across participating sites

Secondary outcomes

  1. Incidence of composite measure of complications

    Time frame: 3 month after surgery

    Estimate of composite measure of complication (revision surgery, infection, non-union).

  2. Adverse events

    Time frame: 3 month after surgery

    Estimate of intervention related adverse events

  3. modified Radiological Union Scale for Tibia [RUST] score),

    Time frame: 2 week, 4 week, 2 months, 3 months, 4 months, 5 months, 6 months post operative.

    Tool for radiographic assessment of fracture healing

  4. Olerud Molander Score

    Time frame: within 48 hours of surgery, 3 month and 6 months after surgery.

    a functional rating scale from 0 (totally impaired) to 100 (completely unimpaired)

  5. EuroQol five dimensions [EQ-5D]

    Time frame: within 48 hours of surgery, 3 month and 6 months after surgery.

    Quality of life measure

  6. short form-12 [SF-12]

    Time frame: within 48 hours of surgery, 3 month and 6 months after surgery.

    Quality of life measure

  7. pain visual analogue score [VAS]

    Time frame: within 48 hours of surgery, 3 month and 6 months after surgery.

    Pain intensity measure

  8. time-to-fracture union

    Time frame: 6 month post operative

    the time between fracture and radiological healing of the fracture

  9. 90 day mortality

    Time frame: 3 month post operative

    Mortality rate after 90 days of the surgery

  10. Bone mineral density

    Time frame: 2 week and 3 month post operative

    Bone mineral density scan

  11. Total cost and QALYs

    Time frame: 3 month post operative

    Measurement of the incremental cost per QALY gained for the more effective treatment option.

Study contacts

Contact information is provided by the study sponsor or research team.

Jessica Duong

CONTACT

[email protected]

403-220-3366

Prism S Schneider

CONTACT

[email protected]

403-944-4518

Sponsors and collaborators

Lead sponsor

University of Calgary

Other

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Mar 12, 2024
Registry last updated
Mar 18, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.